These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 7716447

  • 21. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM, Tsevat J.
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Congenital toxoplasmosis: pediatric approach. Consensus report of the Swiss infectious disease pediatricians].
    Vaudaux B, Rudin C, Kind C, Schaad UB, Gnehm HE, Nadal D, Suter S, Calame A, Hohlfeld P.
    Schweiz Med Wochenschr Suppl; 1995; 65():70S-81S. PubMed ID: 7716456
    [Abstract] [Full Text] [Related]

  • 24. Cost-benefit analysis of screening for toxoplasmosis during pregnancy.
    Lappalainen M, Sintonen H, Koskiniemi M, Hedman K, Hiilesmaa V, Ammälä P, Teramo K, Koskela P.
    Scand J Infect Dis; 1995; 27(3):265-72. PubMed ID: 8539552
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [-Screening for toxoplasmosis in pregnancy-].
    Extermann P.
    Arch Gynecol Obstet; 1995; 256 Suppl():S170-2. PubMed ID: 8619653
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cost-benefit analysis of Helicobacter pylori screening.
    Leivo T, Salomaa A, Kosunen TU, Tuominen R, Färkkilä M, Linna M, Sintonen H.
    Health Policy; 2004 Oct; 70(1):85-96. PubMed ID: 15312711
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Economic evaluation of prenatal carrier screening for fragile X syndrome.
    Vintzileos AM, Ananth CV, Fisher AJ, Smulian JC, Day-Salvatore D, Beazoglou T, Knuppel RA.
    J Matern Fetal Med; 1999 Oct; 8(4):168-72. PubMed ID: 10406300
    [Abstract] [Full Text] [Related]

  • 34. Congenital toxoplasmosis: late pregnancy infections detected by neonatal screening and maternal serological testing at delivery.
    Lago EG, Neto EC, Melamed J, Rucks AP, Presotto C, Coelho JC, Parise C, Vargas PR, Goldbeck AS, Fiori RM.
    Paediatr Perinat Epidemiol; 2007 Nov; 21(6):525-31. PubMed ID: 17937738
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W, Vintzileos AM.
    J Matern Fetal Med; 1999 Nov; 8(6):243-8. PubMed ID: 10582856
    [Abstract] [Full Text] [Related]

  • 37. Screening for thalassemia: an economics viewpoint.
    Indaratna K.
    Southeast Asian J Trop Med Public Health; 1997 Nov; 28 Suppl 3():75-81. PubMed ID: 9640604
    [Abstract] [Full Text] [Related]

  • 38. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD, Wong JB, Muñoz A, Sonnenberg FA.
    Arch Intern Med; 1993 May 10; 153(9):1107-16. PubMed ID: 8481077
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.